Literature DB >> 382645

The role of immunotherapy in the management of patients with malignant melanoma.

J E Goodnight, D L Morton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 382645     DOI： 10.1007/bf01556582

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  66 in total

1.  Effect of intranodular B.C.G. in 22 melanoma patients.

Authors:  L Israël; A Depierre; R Edelstein; J Cros-Decam; P Maury
Journal:  Panminerva Med       Date:  1975 May-Jun       Impact factor: 5.197

2.  Spontaneous regression of human melanoma: clinical and experimental studies.

Authors:  W C SUMNER; A G FORAKER
Journal:  Cancer       Date:  1960 Jan-Feb       Impact factor: 6.860

3.  Proceedings: Immunotherapy of malignant disease: the use of viable sensitized lymphocytes or transfer factor prepared from sensitized lymphocytes.

Authors:  E T Krementz; P W Mansell; M O Hornung; M S Samuels; C A Sutherland; E N Benes
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

4.  Use of vaccinia virus in the treatment of metastatic malignant melanoma.

Authors:  I Hunter-Craig; K A Newton; G Westbury; B W Lacey
Journal:  Br Med J       Date:  1970-05-30

5.  Cellular and humoral immunity against human malignant melanoma.

Authors:  G Fossati; M I Colnaghi; G D Porta; N Cascinelli; U Veronesi
Journal:  Int J Cancer       Date:  1971-09-15       Impact factor: 7.396

6.  Critical analysis of treatment of stage II and stage III melanoma patients with immunotherapy.

Authors:  W R Jewell; J H Thomas; J M Sterchi; P A Morse; L J Humphrey
Journal:  Ann Surg       Date:  1976-05       Impact factor: 12.969

Review 7.  Immunological factors which influence response to immunotherapy in malignant melanoma.

Authors:  D Morton; F R Eilber; R A Malmgren; W C Wood
Journal:  Surgery       Date:  1970-07       Impact factor: 3.982

8.  Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.

Authors:  M H Cohen; J M Jessup; E L Felix; J L Weese; R B Herberman
Journal:  Cancer       Date:  1978-06       Impact factor: 6.860

9.  Clinical and immunologic studies of disseminated BCG infection.

Authors:  S A Rosenberg; C Seipp; H F Sears
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860

10.  Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.

Authors:  G A Currie; T J McElwain
Journal:  Br J Cancer       Date:  1975-02       Impact factor: 7.640
View more
  3 in total

1.  General surgery-important advances in clinical medicine: cutaneous melanoma.

Authors:  R J Thompson; B W Branson
Journal:  West J Med       Date:  1983-02

2.  Adjuvant BCG immunotherapy for malignant melanoma.

Authors:  A H Paterson; D J Willans; L M Jerry; J Hanson; T A McPherson
Journal:  Can Med Assoc J       Date:  1984-10-01       Impact factor: 8.262

Review 3.  Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy.

Authors:  Brendon J Coventry
Journal:  Ther Adv Vaccines Immunother       Date:  2019-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.